Repare Therapeutics Inc. Stock News

Wall Street analysts forecast that Repare Therapeutics Inc. (NASDAQ:RPTX) will announce sales of $2.62 million for the current quarter, Zacks reports. Three analysts have issued estimates for Repare Therapeutics earnings, with the highest sales estimate coming in at $7.40 million and the lowest estimate coming in at $200,000.00. Repare Therapeutics reported sales of $140,000.00 in []

Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) traded up 12.6% during mid-day trading on Tuesday . The company traded as high as $22.96 and last traded at $22.82. 1,223 shares were traded during mid-day trading, a decline of 99% from the average session volume of 170,537 shares. The stock had previously closed at $20.27. A number []

Equities analysts expect Repare Therapeutics Inc. (NASDAQ:RPTX) to post earnings of ($0.74) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Repare Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.84). Repare Therapeutics posted earnings per share […]

Renaissance Technologies LLC bought a new stake in Repare Therapeutics Inc. (NASDAQ:RPTX) in the second quarter, Holdings Channel reports. The institutional investor bought 20,400 shares of the companys stock, valued at approximately $636,000. Several other large investors have also made changes to their positions in the company. FMR LLC raised its holdings in shares of []

Repare Therapeutics Inc. (NASDAQ:RPTX) EVP Michael Zinda sold 20,000 shares of Repare Therapeutics stock in a transaction on Monday, November 15th. The shares were sold at an average price of $27.33, for a total value of $546,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. []

Repare Therapeutics Inc. (NASDAQ:RPTX) Director Thomas Civik acquired 7,500 shares of the firms stock in a transaction on Tuesday, November 16th. The shares were acquired at an average price of $28.08 per share, with a total value of $210,600.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Related Stocks: RPTX ,

Repare Therapeutics (NASDAQ:RPTX) had its target price lifted by equities researchers at Northland Securities from $40.00 to $45.00 in a research report issued on Thursday, The Fly reports. The brokerage presently has an outperform rating on the stock. Northland Securities price objective indicates a potential upside of 66.24% from the companys previous close. Several other []

The shares of Repare Therapeutics Inc (NASDAQ: RPTX) have received a price target of $48 from Stifel. These are the details.

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -18.57% and 39.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal g

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the pres

The stock price of Repare Therapeutics Inc (NASDAQ: RPTX) increased by over 17% during intraday trading today. This is why it happened.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the followi

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar